The dual function of PRMT1 in modulating epithelial-mesenchymal transition and cellular senescence in breast cancer cells through regulation of ZEB1

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Gao, Yanyan ^a   Zhao, Yaping ^a   Zhang, Juechao ^a   Lu, Yang ^a   Liu, Xin ^a   Geng, Pengyu ^a   Huang, Baiqu ^a   Zhang, Yu ^a   Lu, Jun ^a  

^a NORTHEAST NORMAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE; PRMT1 PROTEIN, HUMAN; PROTEIN ARGININE METHYLTRANSFERASE; REPRESSOR PROTEIN; TRANSCRIPTION FACTOR ZEB1; ZEB1 PROTEIN, HUMAN;

ANIMAL; BREAST TUMOR; CANCER STEM CELL; CELL AGING; CELL CYCLE CHECKPOINT; CELL MOTION; DISEASE MODEL; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; MOUSE; PATHOLOGY; PROMOTER REGION; TETRAPLOIDY; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CELL AGING; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL MOVEMENT; DISEASE MODELS, ANIMAL; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONES; HUMANS; MICE; NEOPLASTIC STEM CELLS; PROMOTER REGIONS, GENETIC; PROTEIN-ARGININE N-METHYLTRANSFERASES; REPRESSOR PROTEINS; TETRAPLOIDY; ZINC FINGER E-BOX-BINDING HOMEOBOX 1;

EID: 84955468768     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep19874     Document Type: Article

References (53)

1. Fan, L. et al. Breast cancer in China. Lancet Oncol 15, e279-89 (2014).
2. Hay, E. D. An overview of epithelio-mesenchymal transformation. Acta Anat (Basel) 154, 8-20 (1995).
3. Kalluri, R. & Weinberg, R. A. The basics of epithelial-mesenchymal transition. J Clin Invest 119, 1420-8 (2009).
4. Bonnomet, A. et al. A dynamic in vivo model of epithelial-to-mesenchymal transitions in circulating tumor cells and metastases of breast cancer. Oncogene 31, 3741-53 (2012).
5. Trimboli, A. J. et al. Direct evidence for epithelial-mesenchymal transitions in breast cancer. Cancer Res 68, 937-45 (2008).
6. Sarrio, D. et al. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res 68, 989-97 (2008).
7. Prat, A. et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 12, R68 (2010).
8. Davis, F. M., Stewart, T. A., Thompson, E. W. & Monteith, G. R. Targeting EMT in cancer: Opportunities for pharmacological intervention. Trends Pharmacol Sci 35, 479-88 (2014).
9. Smit, M. A. & Peeper, D. S. Epithelial-mesenchymal transition and senescence: Two cancer-related processes are crossing paths. Aging (Albany NY) 2, 735-41 (2010).
10. Ansieau, S. et al. Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence. Cancer Cell 14, 79-89 (2008).
11. Tran, P. T. et al. Twist1 suppresses senescence programs and thereby accelerates and maintains mutant Kras-induced lung tumorigenesis. PLoS Genet 8, e1002650 (2012).
12. Ohashi, S. et al. Epidermal growth factor receptor and mutant p53 expand an esophageal cellular subpopulation capable of epithelialto-mesenchymal transition through ZEB transcription factors. Cancer Res 70, 4174-84 (2010).
13. Emadi Baygi, M., Soheili, Z. S., Schmitz, I., Sameie, S. & Schulz, W. A. Snail regulates cell survival and inhibits cellular senescence in human metastatic prostate cancer cell lines. Cell Biol Toxicol 26, 553-67 (2010).
14. Liu, Y., El-Naggar, S., Darling, D. S., Higashi, Y. & Dean, D. C. Zeb1 links epithelial-mesenchymal transition and cellular senescence. Development 135, 579-88 (2008).
15. Guo, A. et al. Immunoaffinity enrichment and mass spectrometry analysis of protein methylation. Mol Cell Proteomics 13, 372-87 (2014).
16. Bedford, M. T. & Clarke, S. G. Protein arginine methylation in mammals: Who, what, and why. Mol Cell 33, 1-13 (2009).
17. Yamagata, K. et al. Arginine methylation of FOXO transcription factors inhibits their phosphorylation by Akt. Mol Cell 32, 221-31 (2008).
18. Le Romancer, M. et al. Regulation of estrogen rapid signaling through arginine methylation by PRMT1. Mol Cell 31, 212-21 (2008).
19. Boisvert, F. M., Dery, U., Masson, J. Y. & Richard, S. Arginine methylation of MRE11 by PRMT1 is required for DNA damage checkpoint control. Genes Dev 19, 671-6 (2005).
20. Boisvert, F. M., Rhie, A., Richard, S. & Doherty, A. J. The GAR motif of 53BP1 is arginine methylated by PRMT1 and is necessary for 53BP1 DNA binding activity. Cell Cycle 4, 1834-41 (2005).
21. Strahl, B. D. et al. Methylation of histone H4 at arginine 3 occurs in vivo and is mediated by the nuclear receptor coactivator PRMT1. Curr Biol 11, 996-1000 (2001).
22. Wang, H. et al. Methylation of histone H4 at arginine 3 facilitating transcriptional activation by nuclear hormone receptor. Science 293, 853-7 (2001).
23. Baldwin, R. M., Morettin, A. & Cote, J. Role of PRMTs in cancer: Could minor isoforms be leaving a mark? World J Biol Chem 5, 115-29 (2014).
24. Cheung, N., Chan, L. C., Thompson, A., Cleary, M. L. & So, C. W. Protein arginine-methyltransferase-dependent oncogenesis. Nat Cell Biol 9, 1208-15 (2007).
25. Mathioudaki, K. et al. Clinical evaluation of PRMT1 gene expression in breast cancer. Tumour Biol 32, 575-82 (2011).
26. Mathioudaki, K. et al. The PRMT1 gene expression pattern in colon cancer. Br J Cancer 99, 2094-9 (2008).
27. Seligson, D. B. et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 435, 1262-6 (2005).
28. Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J. & Clarke, M. F. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100, 3983-8 (2003).
29. Mani, S. A. et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704-15 (2008).
30. Margolis, R. L., Lohez, O. D. & Andreassen, P. R. G1 tetraploidy checkpoint and the suppression of tumorigenesis. J Cell Biochem 88, 673-83 (2003).
31. Sherwood, S. W., Rush, D., Ellsworth, J. L. & Schimke, R. T. Defining cellular senescence in IMR-90 cells: A flow cytometric analysis. Proc Natl Acad Sci USA 85, 9086-90 (1988).
32. Mason, D. X., Jackson, T. J. & Lin, A. W. Molecular signature of oncogenic ras-induced senescence. Oncogene 23, 9238-46 (2004).
33. Shelton, D. N., Chang, E., Whittier, P. S., Choi, D. & Funk, W. D. Microarray analysis of replicative senescence. Curr Biol 9, 939-45 (1999).
34. Stein, G. H., Drullinger, L. F., Robetorye, R. S., Pereira-Smith, O. M. & Smith, J. R. Senescent cells fail to express cdc2, cycA, and cycB in response to mitogen stimulation. Proc Natl Acad Sci USA 88, 11012-6 (1991).
35. Tang, J. et al. PRMT1 is the predominant type I protein arginine methyltransferase in mammalian cells. J Biol Chem 275, 7723-30 (2000).
36. Scorilas, A., Black, M. H., Talieri, M. & Diamandis, E. P. Genomic organization, physical mapping, and expression analysis of the human protein arginine methyltransferase 1 gene. Biochem Biophys Res Commun 278, 349-59 (2000).
37. Goulet, I., Gauvin, G., Boisvenue, S. & Cote, J. Alternative splicing yields protein arginine methyltransferase 1 isoforms with distinct activity, substrate specificity, and subcellular localization. J Biol Chem 282, 33009-21 (2007).
38. Baldwin, R. M., Morettin, A., Paris, G., Goulet, I. & Cote, J. Alternatively spliced protein arginine methyltransferase 1 isoform PRMT1v2 promotes the survival and invasiveness of breast cancer cells. Cell Cycle 11, 4597-612 (2012).
39. Avasarala, S. et al. PRMT1 Is a Novel Regulator of Epithelial-Mesenchymal-Transition in Non-small Cell Lung Cancer. J Biol Chem 290, 13479-89 (2015).
40. Xu, J. et al. Arginine Methylation Initiates BMP-Induced Smad Signaling. Mol Cell 51, 5-19 (2013).
41. Yu, Z., Chen, T., Hebert, J., Li, E. & Richard, S. A mouse PRMT1 null allele defines an essential role for arginine methylation in genome maintenance and cell proliferation. Mol Cell Biol 29, 2982-96 (2009).
42. Yoshimatsu, M. et al. Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancers. Int J Cancer 128, 562-73 (2011).
43. Weiss, R. H. p21Waf1/Cip1 as a therapeutic target in breast and other cancers. Cancer Cell 4, 425-9 (2003).
44. Shay, J. W. & Roninson, I. B. Hallmarks of senescence in carcinogenesis and cancer therapy. Oncogene 23, 2919-33 (2004).
45. Li, Q. Q. et al. Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells. Clin Cancer Res 15, 2657-65 (2009).
46. Derksen, P. W. et al. Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell 10, 437-49 (2006).
47. Campisi, J. Senescent cells, tumor suppression, and organismal aging: Good citizens, bad neighbors. Cell 120, 513-22 (2005).
48. Hou, P. et al. LincRNA-ROR induces epithelial-to-mesenchymal transition and contributes to breast cancer tumorigenesis and metastasis. Cell Death Dis 5, e1287 (2014).
49. Li, L. et al. SHON, a novel secreted protein, regulates epithelial-mesenchymal transition through transforming growth factor-beta signaling in human breast cancer cells. Int J Cancer 136, 1285-95 (2015).
50. Brabletz, T., Jung, A., Spaderna, S., Hlubek, F. & Kirchner, T. Opinion: Migrating cancer stem cells-an integrated concept of malignant tumour progression. Nat Rev Cancer 5, 744-9 (2005).
51. Zhang, J. et al. SOX4 induces epithelial-mesenchymal transition and contributes to breast cancer progression. Cancer Res 72, 4597-608 (2012).
52. Zhang, Y. et al. Mitogen-activated protein kinase p38 and retinoblastoma protein signalling is required for DNA damage-mediated formation of senescence-associated heterochromatic foci in tumour cells. FEBS J 280, 4625-39 (2013).
53. Dimri, G. P. et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 92, 9363-7 (1995).